Evaluating kidney cancer aggressiveness using Rubidium Chloride PET scan imaging in patients with renal cell carcinoma

2 1 1 1

What is this study about?

This clinical trial focuses on studying kidney carcinoma, a type of cancer that develops in the kidneys. The study uses Rubidium Chloride, a radioactive substance that helps create detailed images of the kidney tumors using a special scanning technique called Positron Emission Tomography (PET). This imaging method allows doctors to examine how aggressive the kidney cancer is without requiring additional invasive procedures.

The purpose of this research is to determine whether the amount of Rubidium-82 absorbed by the tumor can accurately indicate how aggressive the cancer is. During the study, participants will receive a single injection of Rubidium Chloride through a vein (given intravenously) before undergoing the PET scan. The maximum amount of radioactive substance used will be 2300 MBq (megabecquerels, a measure of radioactivity).

The scanning procedure will take place before patients undergo their planned surgery for tumor removal. The images obtained from the PET scan will be compared with the actual tumor tissue examined after surgery to verify if this new imaging method can accurately predict the aggressiveness of kidney tumors. This information could help doctors make better treatment decisions for future patients with kidney cancer.

1 Initial <b>PET scan</b> preparation

You will receive an intravenous injection of rubidium chloride, a substance that helps create detailed images of your kidneys

The injection will be administered through a vein in your arm

This substance allows the scanning device to create detailed pictures of your kidney tumor

2 <b>PET imaging</b> procedure

You will lie still on the scanning table while the PET machine takes images of your kidneys

The scan will measure how the rubidium moves through your kidney tissue

The imaging process will focus on your kidney tumor, which should be between 2 and 7 centimeters in size

3 Surgical procedure

After the imaging is complete, you will undergo the planned surgical removal of the kidney tumor

The surgery will be performed according to standard medical procedures

The removed tumor tissue will be examined in the laboratory

4 Follow-up assessment

Your kidney function will be monitored through blood tests

A follow-up examination will occur three months after the surgery

The medical team will measure your kidney function by checking creatinine clearance (a blood test that shows how well your kidneys are working)

Who Can Join the Study?

You must be at least 18 years old
You must be willing to sign a written consent form to participate in the study
You must have French Social Security coverage
You must have either a suspected or confirmed kidney tumor that requires surgery
Your kidney tumor must be between 2 and 7 centimeters in size and show specific features on imaging tests (appears as a highly vascular lesion that enhances with contrast similar to kidney tissue on CT scan)
You must be willing and able to:
- Attend all scheduled medical visits
- Follow treatment plans
- Complete required laboratory tests
- Comply with other study procedures

Who Cannot Join the Study?

Age below 18 years or above 64 years
Patients who are pregnant or breastfeeding
Previous history of other types of cancer
Patients who cannot undergo PET scanning (a type of medical imaging that uses small amounts of radioactive material)
Patients with severe kidney dysfunction other than cancer
Patients who have received any cancer treatment in the last 30 days
Known allergy to medical contrast agents or radioactive tracers
Inability to lie still for the duration of the scanning procedure
Patients with metal implants or devices that could interfere with imaging
Patients who cannot provide informed consent
Participation in other clinical trials within the past 30 days

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name	City	Country	Status
Hopital Beaujon	Clichy	France

Trial status

Country	Status	Recruitment Start
France	Recruiting	02.06.2025

Trial locations

Investigated drugs:

RUBIDIUM CHLORIDE

Rubidium-82 (82-Rb) is a radioactive tracer used in Positron Emission Tomography (PET) scanning. This imaging agent helps doctors see how the kidneys function and evaluate kidney tumors. When injected into the body, it allows the PET scanner to create detailed images that can show differences between aggressive and less aggressive forms of kidney cancer. The substance is safe and quickly eliminated from the body after the scan is complete.

Investigated diseases:

Renal cell carcinoma

Kidney carcinoma – A type of cancer that begins in the cells of the kidneys, specifically in the small tubes that filter blood and remove waste products. The disease typically starts as a small growth in one kidney that can gradually increase in size over time. As the condition progresses, abnormal cells multiply and form a tumor within the kidney tissue. Kidney carcinoma can develop in people of any age, though it’s more common in older adults. The disease may affect one or, less commonly, both kidneys simultaneously. This cancer can vary in its growth rate and characteristics, with different subtypes showing distinct patterns of development.

Trial ID:

2024-514085-39-00

Protocol code:

APHP231442

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Evaluating kidney cancer aggressiveness using Rubidium Chloride PET scan imaging in patients with renal cell carcinoma

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?